RT Journal Article
SR Electronic
T1 Elevated RDW is Associated with Increased Mortality Risk in COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.05.20091702
DO 10.1101/2020.05.05.20091702
A1 Foy, Brody H.
A1 Carlson, Jonathan C.T.
A1 Reinertsen, Erik
A1 Valls, Raimon Padros
A1 Lopez, Roger Pallares
A1 Palanques-Tost, Eric
A1 Mow, Christopher
A1 Westover, M. Brandon
A1 Aguirre, Aaron D.
A1 Higgins, John M.
YR 2020
UL http://medrxiv.org/content/early/2020/05/12/2020.05.05.20091702.abstract
AB Background Coronavirus disease 2019 (COVID-19) is an acute respiratory illness with a high rate of hospitalization and mortality. Prognostic biomarkers are urgently needed. Red blood cell distribution width (RDW), a component of complete blood counts that reflects cellular volume variation, has been shown to be associated with elevated risk for morbidity and mortality in a wide range of diseases.Methods We retrospectively studied the relationship between RDW and COVID-19 mortality risk for 1198 adult patients diagnosed with SARS-CoV-2 at 4 Partners Healthcare Network Hospitals between March 4, 2020, and April 28, 2020.Results Elevated RDW (> 14.5%) was associated with increased mortality in patients of all ages with a risk ratio of 2.5 (95% CI, 2.3 – 2.8). Stratified by age, the risk ratio was 6.2 (4.4 – 7.9, N = 312) < 50 years, 3.2 (2.5 – 4.1, N = 230) 50-60, 2.3 (1.6 – 3.1, N = 236) 60-70, 1.2 (0.7 – 1.8, N = 203) 70-80, and 1.9 (1.5 – 2.3, N = 216) > 80 years. RDW was significantly associated with mortality in Cox proportional hazards models adjusted for age, D-Dimer, absolute lymphocyte count, and common comorbidities (p < 1e-4 for RDW in all cases). Patients whose RDW increased during admission had a ~3-fold elevation in mortality risk compared to those whose RDW did not change.Conclusions Elevated RDW at diagnosis and an increase in RDW during admission are both associated with increased mortality risk for adult COVID-19 patients at a large academic medical center network.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by funding from the One Brave Idea Initiative and the CRICO Risk Management Fund.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSummary data related to all figures and tables is available upon reasonable request to the author. Due to the IRB, individual patient data cannot be provided.